Nearly 200 teens from across the country -- nearly half living with cystic fibrosis -- participated in the Foundation's Virtual Teen Advocacy Day to advocate for the CF community.
Cost effectiveness analysis must be used carefully and as part of a comprehensive evaluation of the value a treatment, such as highly effective modulators, provide to people living with cystic fibrosis.
A cystic fibrosis diagnosis must not disqualify an individual from life-saving care.
More than 160 organizations join the Cystic Fibrosis Foundation in asking Congress to expand paid family and medical leave for people with chronic conditions, such as cystic fibrosis.
More than 200 advocates gathered on Capitol Hill during the Cystic Fibrosis Foundation's 14th Annual March on the Hill, championing antibiotic research and development and other policy needs on behalf of people with CF.
On Monday, April 1, the CF Foundation joined 16 other patient and consumer groups in filing an amicus brief supporting vital patient protections and coverage expansion included in the Affordable Care Act in the appeal of the Texas v. United States decision, which struck down the constitutionality of the health care law in 2018.
Yesterday, the U.S. Department of Health and Human Services finalized a rule expanding short-term, limited-duration insurance plans -- threatening access to adequate, affordable coverage for people with cystic fibrosis who rely on the individual marketplace.
Responding to the Trump administration's recent decision to freeze risk adjustment payments, the Cystic Fibrosis Foundation joined 13 other nonpartisan patient groups to voice disappointment in the latest administrative efforts to undermine adequate and affordable health care for people with pre-existing conditions.
The Cystic Fibrosis Foundation responds to the Institute for Clinical and Economic Review's assessment of the comparative clinical effectiveness and value of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
The Institute for Clinical and Economic Review (ICER) developed an assessment of the comparative clinical effectiveness and value of cystic fibrosis therapies. The Foundation provided input to help inform this process.